ashibio, Inc.
- Biotech or pharma, therapeutic R&D
āshibio is developing novel therapies for patients with rare bone and connective tissue disorders that have the potential to prevent the onset of symptoms or slow the progression of disease. The company has initiated a Phase 2/3 trial of its lead asset, andecaliximab, in patients with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by progressive heterotopic ossification (HO), a pathological condition characterized by abnormal bone formation in muscle and soft tissues. āshibio has also initiated a development program in non-hereditary heterotopic ossification (NHHO), a severely disabling condition for which there are no approved therapies. The company is also in the process of in-licensing a second asset for another rare genetic bone disease.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}